All News Top News Dec 14, 2018 Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications Learn More Share Top News Nov 28, 2018 Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications Learn More Share Top News Nov 27, 2018 Teva’s Generic Epinephrine Injection Now Available in Limited Quantity in the US Learn More Share Top News Nov 1, 2018 Teva Reports Third Quarter 2018 Financial Results Learn More Share Top News Oct 21, 2018 Teva and New Jersey Governor Murphy Formalize North America Headquarters Move with Ceremony in Israel Learn More Share
Top News Dec 14, 2018 Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications Learn More
Top News Nov 28, 2018 Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications Learn More
Top News Nov 27, 2018 Teva’s Generic Epinephrine Injection Now Available in Limited Quantity in the US Learn More
Top News Oct 21, 2018 Teva and New Jersey Governor Murphy Formalize North America Headquarters Move with Ceremony in Israel Learn More